Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Free Report) was the target of a large decrease in short interest during the month of June. As of June 15th, there was short interest totalling 75,400 shares, a decrease of 7.8% from the May 31st total of 81,800 shares. Based on an average daily volume of 653,500 shares, the short-interest ratio is currently 0.1 days.
Wall Street Analyst Weigh In
Separately, Oppenheimer raised Avalo Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, April 16th.
Read Our Latest Analysis on Avalo Therapeutics
Avalo Therapeutics Stock Down 5.5 %
Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) last issued its quarterly earnings data on Monday, May 13th. The company reported ($5.98) EPS for the quarter, missing analysts’ consensus estimates of ($1.18) by ($4.80). Avalo Therapeutics had a negative return on equity of 1,439.87% and a negative net margin of 1,639.50%. Research analysts predict that Avalo Therapeutics will post -0.91 EPS for the current fiscal year.
Institutional Investors Weigh In On Avalo Therapeutics
Institutional investors have recently modified their holdings of the stock. Acadian Asset Management LLC purchased a new stake in Avalo Therapeutics during the 3rd quarter valued at $34,000. Affinity Asset Advisors LLC bought a new stake in shares of Avalo Therapeutics during the 1st quarter worth approximately $218,000. Finally, Ikarian Capital LLC purchased a new position in Avalo Therapeutics during the 1st quarter valued at $1,015,000. 87.06% of the stock is owned by institutional investors.
About Avalo Therapeutics
Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.
Recommended Stories
- Five stocks we like better than Avalo Therapeutics
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- 3 Stocks Upgraded by Analysts: Home Depot, U.S. Steel, Alcoa
- How to Invest in Blue Chip Stocks
- NVIDIA and TSM Stock: Is Semiconductor Sector Momentum Slowing?
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Palo Alto Networks Stock Gains AI-Powered Cybersecurity Solutions
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.